Japan Pharma Database
Pricing: Japan Database: $15,000/- subscription p/a
Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets due to:
1. Operations of various MNCs who generate significant amount of revenue but do not disclose their sales – Market Research Agencies has their limitations; no projections
2. Disclosure of Clinical trial data – is limited/not detailed and is shared after a long gap.
3. Lack of equivalent sites such as clinicaltrials.gov, FDA’s Orange book, etc. – company reports, various categories of CT data available at scattered sources. Mostly in Japanese.
4. Very Difficult to get patent expiry info. from JP cos - Multiple patent extension, NO reliable Source in public domain
5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas companies.
6. Language
Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets due to:
1. Operations of various MNCs who generate significant amount of revenue but do not disclose their sales – Market Research Agencies has their limitations; no projections
2. Disclosure of Clinical trial data – is limited/not detailed and is shared after a long gap.
3. Lack of equivalent sites such as clinicaltrials.gov, FDA’s Orange book, etc. – company reports, various categories of CT data available at scattered sources. Mostly in Japanese.
4. Very Difficult to get patent expiry info. from JP cos - Multiple patent extension, NO reliable Source in public domain
5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas companies.
6. Language
More Publications
Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma
US$ 2,500.00
January 2014
141 pages
Japan Pharma Outlook 2015: 2015 –Year to Watch Out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives
US$ 2,000.00
January 2015
153 pages
Japan Pharma Outlook 2016: JP Giants leaning in for becoming a Speciality Global Pharma
US$ 2,500.00
March 2016
91 pages
New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan
US$ 4,000.00
January 2015
65 pages
